Eisai, Biogen announce U.S. availability of LEQEMBI IQLIK

Eisai Co. (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, U.S. brand name: LEQEMBI IQLIKTM, is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer’s disease in patients with Mild Cognitive Impairment or mild dementia stage of disease. After 18 months of LEQEMBI intravenous treatment at 10 mg/kg every two weeks, patients may either continue IV infusions at 10 mg/kg once every four weeks or start the new weekly 360 mg subcutaneous injection using the LEQEMBI IQLIK autoinjector.